"Our goal is to lead the innovation and development of true continuous, transmural lesions anywhere in the heart. Our primary technologies under development have been ultra-low temperature cryo (ULTC) and electroporation (PFA)," said Olav Bergheim, President and CEO of Adagio Medical.
The company reports the first PsAF patient was successfully treated with its new One Shot+™ cryoablation catheter in a procedure that utilizes only anatomical markers with limited usage of fluorographic imaging and eliminates the need for electromagnetic mapping.
Medtronic Initiates Global Trial Evaluating Cryoablation to Treat Persistent Atrial Fibrillation
Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary vein...
Medical Device News Magazine keeps our readers up-to-date on breaking medical device industry news and more!